{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:37:18Z","timestamp":1771659438939,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,2,2]],"date-time":"2011-02-02T00:00:00Z","timestamp":1296604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s10792-011-9430-3","type":"journal-article","created":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T13:20:41Z","timestamp":1296566441000},"page":"165-173","source":"Crossref","is-referenced-by-count":47,"title":["Adalimumab (Humira\u2122): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology"],"prefix":"10.1007","volume":"31","author":[{"given":"Piergiorgio","family":"Neri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Zucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"Allegri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Lettieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,2]]},"reference":[{"key":"9430_CR1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev.iy.10.040192.002211","volume":"10","author":"P Vassalli","year":"1992","unstructured":"Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411\u2013452","journal-title":"Annu Rev Immunol"},{"key":"9430_CR2","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1126\/science.1071924","volume":"296","author":"G Chen","year":"2002","unstructured":"Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science. 296:1634\u20131635","journal-title":"Science."},{"key":"9430_CR3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/322547a0","volume":"322","author":"J Saklatvala","year":"1986","unstructured":"Saklatvala J (1986) Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 322:547\u2013549","journal-title":"Nature."},{"key":"9430_CR4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.410230405","volume":"23","author":"KW Selmaj","year":"1988","unstructured":"Selmaj KW, Raine CS (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23:339\u2013346","journal-title":"Ann Neurol"},{"key":"9430_CR5","first-page":"3131","volume":"32","author":"RB Nussenblatt","year":"1991","unstructured":"Nussenblatt RB (1991) Proctor Lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications. Invest Ophthalmol Vis Sci. 32:3131\u20133141","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"9430_CR6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/eye.1992.93","volume":"6","author":"JV Forrester","year":"1992","unstructured":"Forrester JV (1992) Duke-Elder lecture: new concepts on the role of autoimmunity in the pathogenesis of uveitis. Eye. 6:433\u2013446","journal-title":"Eye."},{"key":"9430_CR7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.4049\/jimmunol.136.3.928","volume":"136","author":"RR Caspi","year":"1986","unstructured":"Caspi RR, Roberge FG, McAllister CG et al (1986) T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol 136:928\u2013933","journal-title":"J Immunol"},{"key":"9430_CR8","first-page":"3884","volume":"35","author":"S Nakamura","year":"1994","unstructured":"Nakamura S, Yamakawa T, Sugita M et al (1994) The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 35:3884\u20133889","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"9430_CR9","first-page":"2211","volume":"37","author":"G Sartani","year":"1996","unstructured":"Sartani G, Silver PB, Rizzo LV et al (1996) Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 37:2211\u20132218","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"9430_CR10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","volume":"33","author":"M Santos Lacomba","year":"2001","unstructured":"Santos Lacomba M, Marcos Martin C et al (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 33:251\u2013255","journal-title":"Ophthalmic Res."},{"issue":"3","key":"9430_CR11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2006.04.016","volume":"142","author":"JK Ahn","year":"2006","unstructured":"Ahn JK, Yu HG, Chung H, Park YG (2006) Intraocular cytokine environment in active Beh\u00e7et uveitis. Am J Ophthalmol 142(3):429\u2013434","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"9430_CR12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/09273940590950990","volume":"13","author":"M Kramer","year":"2005","unstructured":"Kramer M, Goldenberg-Cohen N, Axer-Siegel R, Weinberger D, Cohen Y, Monselise Y (2005) Inflammatory reaction in acute retinal artery occlusion: cytokine levels in aqueous humor and serum. Ocul Immunol Inflamm. 13(4):305\u2013310","journal-title":"Ocul Immunol Inflamm."},{"issue":"2","key":"9430_CR13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1185\/030079903125002847","volume":"20","author":"V P\u00e9rez-Guijo","year":"2004","unstructured":"P\u00e9rez-Guijo V, Santos-Lacomba M, S\u00e1nchez-Hern\u00e1ndez M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Est\u00e9vez E (2004) Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 20(2):155\u2013157","journal-title":"Curr Med Res Opin"},{"key":"9430_CR14","first-page":"1689","volume":"16","author":"Y Xu","year":"2010","unstructured":"Xu Y, Chen W, Lu H, Hu X, Li S, Wang J, Zhao L (2010) The expression of cytokines in the aqueous humor and serum during endotoxin-induced uveitis in C3H\/HeN mice. Mol Vis. 16:1689\u20131695 Aug 21","journal-title":"Mol Vis."},{"key":"9430_CR15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","volume":"14","author":"M Feldmann","year":"1996","unstructured":"Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397\u2013440","journal-title":"Annu Rev Immunol"},{"key":"9430_CR16","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med 340:1398\u20131405","journal-title":"N Engl J Med"},{"key":"9430_CR17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253\u2013259","journal-title":"N Engl J Med"},{"issue":"10","key":"9430_CR18","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","volume":"56","author":"LL Lim","year":"2007","unstructured":"Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthr Rheum 56(10):3248\u20133252","journal-title":"Arthr Rheum"},{"key":"9430_CR19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/jaut.1998.0197","volume":"11","author":"AD Dick","year":"1998","unstructured":"Dick AD, Duncan L, Hale G et al (1998) Neutralizing TNF-\u03b1lpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun 11:255\u2013264","journal-title":"J Autoimmun"},{"issue":"12","key":"9430_CR20","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00296-009-1179-x","volume":"30","author":"C Yue","year":"2010","unstructured":"Yue C, You X, Zhao L et al (2010) The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17\/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 30(12):1553\u20131557","journal-title":"Rheumatol Int"},{"issue":"4","key":"9430_CR21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","volume":"36","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Claudepierre P, Wordsworth P et al (2009) Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 36(4):801\u2013808","journal-title":"J Rheumatol"},{"issue":"2","key":"9430_CR22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ard.2009.111856","volume":"69","author":"F Bosch van den","year":"2010","unstructured":"van den Bosch F, Manger B, Goupille P et al (2010) Effectiveness of adalimumab in treating patients with active psoriatic arthritis (PsA) and predictors of good clinical responses for arthritis, skin, and nail lesions. Ann Rheum Dis 69(2):394\u2013399","journal-title":"Ann Rheum Dis"},{"key":"9430_CR23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ICU.0b013e3282f03d42","volume":"18","author":"F Imrie","year":"2007","unstructured":"Imrie F, Dick AD (2007) Biologics in the treatment of uveitis. Curr Opin Ophthalmol 18:481\u2013486","journal-title":"Curr Opin Ophthalmol"},{"key":"9430_CR24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/ard.2007.069872","volume":"66","author":"RF Vollenhoven van","year":"2007","unstructured":"van Vollenhoven RF (2007) Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 66:849\u2013851","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"9430_CR25","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/eye.2009.203","volume":"23","author":"N Dhingra","year":"2009","unstructured":"Dhingra N, Morgan J, Dick AD (2009) Switching biologic agents for uveitis. Eye (Lond) 23(9):1868\u20131870","journal-title":"Eye (Lond)"},{"issue":"2","key":"9430_CR26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117(2):244\u2013279","journal-title":"Pharmacol Ther"},{"issue":"3","key":"9430_CR27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","volume":"91","author":"S Biester","year":"2007","unstructured":"Biester S, Deuter C, Michels H et al (2007) Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91(3):319\u2013324","journal-title":"Br J Ophthalmol"},{"key":"9430_CR28","doi-asserted-by":"crossref","unstructured":"Wiens A, Correr CJ, Venson R et al (2010) A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. Rheumatol Int 30(8):1063\u20131070","DOI":"10.1007\/s00296-009-1111-4"},{"key":"9430_CR29","first-page":"303","volume":"3","author":"J Schmitt","year":"2009","unstructured":"Schmitt J, Wozel G (2009) Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics 3:303\u2013318","journal-title":"Biologics"},{"key":"9430_CR30","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","volume":"63","author":"LBA Putte van de","year":"2004","unstructured":"van de Putte LBA, Atkins C, Malaise M et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508\u2013516","journal-title":"Ann Rheum Dis"},{"key":"9430_CR31","first-page":"2288","volume":"29","author":"A Broeder den","year":"2002","unstructured":"den Broeder A, van de Putte LBA, Rau R et al (2002) A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-\u03b1 antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29:2288\u20132298","journal-title":"J Rheumatol"},{"key":"9430_CR32","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"5","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthr Rheum 5:1400\u20131411","journal-title":"Arthr Rheum"},{"key":"9430_CR33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","volume":"1","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor \u03b1 monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthr Rheum 1:35\u201345","journal-title":"Arthr Rheum"},{"key":"9430_CR34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/ard.2005.044404","volume":"65","author":"ME Weinblatt","year":"2006","unstructured":"Weinblatt ME, Keystone EC, Furst DE et al (2006) Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study. Ann Rheum Dis 65:753\u2013759","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"9430_CR35","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/rheumatology\/kel208","volume":"45","author":"I Olivieri","year":"2006","unstructured":"Olivieri I, Scarano E, Gigliotti P et al (2006) Successful treatment of juvenile-onset HLA-B27-associated severe and refractory heel thesitis with adalimumab documented by magnetic resonance imaging. Rheumatology 45(10):1315\u20131317","journal-title":"Rheumatology"},{"key":"9430_CR36","first-page":"1374","volume":"32","author":"AB Adams","year":"2005","unstructured":"Adams AB, Kazim M, Lehman TJA (2005) Treatment of orbital myositis with adalimumab (Humira). J Rheumatol 32:1374\u20131375","journal-title":"J Rheumatol"},{"key":"9430_CR37","first-page":"1100","volume":"35","author":"AF Vos de","year":"1994","unstructured":"de Vos AF, van Haren MAC, Verhagen C et al (1994) Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 35:1100\u20131106","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9430_CR38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0014-4835(95)80011-5","volume":"60","author":"AF Vos de","year":"1995","unstructured":"de Vos AF, van Haren MAC, Verhagen C et al (1995) TNF-induced uveitis in the Lewis rat is associated with intraocular interleukin 6 production. Exp Eye Res 60:199\u2013207","journal-title":"Exp Eye Res"},{"key":"9430_CR39","first-page":"47","volume":"133","author":"JT Rosenbaum","year":"1988","unstructured":"Rosenbaum JT, Howes EL, Rubin RM et al (1988) Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol 133:47\u201353","journal-title":"Am J Pathol"},{"issue":"1","key":"9430_CR40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3122\/jabfm.17.1.59","volume":"17","author":"MH Ebell","year":"2004","unstructured":"Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, Bowman M (2004) Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 17(1):59\u201367","journal-title":"J Am Board Fam Pract"},{"key":"9430_CR41","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509\u2013516","journal-title":"Am J Ophthalmol"},{"key":"9430_CR42","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.exer.2004.06.001","volume":"79","author":"MC Avunduk","year":"2004","unstructured":"Avunduk MC, Avunduk AM, Oztekin E et al (2004) Etanercept treatment in the endotoxin-induced uveitis of rats. Exp Eye Res 79:357\u2013365","journal-title":"Exp Eye Res"},{"key":"9430_CR43","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1167\/iovs.02-0589","volume":"44","author":"K Koizumi","year":"2003","unstructured":"Koizumi K, Poulaki V, Doehmen S et al (2003) Contribution of TNF-\u03b1 to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci 44:2184\u20132191","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"9430_CR44","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, R\u00f8devand E, Holck P et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696\u2013701","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"9430_CR45","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","volume":"21","author":"B Mushtaq","year":"2007","unstructured":"Mushtaq B, Saeed T, Situnayake RD et al (2007) Adalimumab for sight-threatening uveitis in Beh\u00e7et\u2019s disease. Eye (Lond) 21(6):824\u2013825","journal-title":"Eye (Lond)"},{"key":"9430_CR46","doi-asserted-by":"crossref","unstructured":"Takase K, Ohno S, Ideguchi H et al (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Beh\u00e7et disease-related uveitis. Rheumatol Int 31(2):243\u2013245","DOI":"10.1007\/s00296-009-1178-y"},{"issue":"3","key":"9430_CR47","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jop.2007.0104","volume":"24","author":"M Diaz-Llopis","year":"2008","unstructured":"Diaz-Llopis M, Garc\u00eda-Delpech S, Salom D et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24(3):351\u2013361","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"9430_CR48","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bjo.2006.094698","volume":"91","author":"D Doycheva","year":"2007","unstructured":"Doycheva D, Deuter C, Stuebiger N et al (2007) Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 91(2):180\u2013184","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"9430_CR49","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","volume":"47","author":"P Tynj\u00e4l\u00e4","year":"2008","unstructured":"Tynj\u00e4l\u00e4 P, Kotaniemi K, Lindahl P et al (2008) Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 47(3):339\u2013344","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"9430_CR50","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2009.12.011","volume":"117","author":"S Androudi","year":"2010","unstructured":"Androudi S, Tsironi E, Kalageropoulos C et al. (2010) Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmol 117(8):1612\u20131616","journal-title":"Ophthalmol"},{"key":"9430_CR51","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1167\/iovs.02-1156","volume":"44","author":"M Robertson","year":"2003","unstructured":"Robertson M, Liversidge J, Forrester J et al (2003) Neutralising TNF-\u03b1lpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 44:3034\u20133041","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-011-9430-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-011-9430-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-011-9430-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T01:50:49Z","timestamp":1685929849000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-011-9430-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["9430"],"URL":"https:\/\/doi.org\/10.1007\/s10792-011-9430-3","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,2]]}}}